Compare Bristol-Myers Squibb Co (BMY) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs LyondellBasell Industries NV — how do they compare? Bristol-Myers Squibb Co trades at $58.31 (market cap $116.30B), while LyondellBasell Industries NV trades at $58.57 (market cap $18.90B). The key difference: Bristol-Myers Squibb Co is far larger — about 6.2× LyondellBasell Industries NV's market cap, and LyondellBasell Industries NV pays the higher dividend (7.04%). Which is the better fit depends on your goals.
| BMY | LYB | |
|---|---|---|
Market Cap | $116.30B | $18.90B |
Sector | Health | Basic Materials |
52-Week High | $62.37 | $82.38 |
52-Week Low | $42.60 | $42.28 |
Enterprise Value | $152.24B | $30.52B |
Dividend Yield | 4.42% | 7.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
LyondellBasell (LYB) trades at $58.32, up 3.49% today, with a bullish technical signal supported by moving averages and ADX indicators. The company reported mixed earnings, beating estimates in Q1 2026 but missing in Q4 2025, while revenue has declined from $50.5B in 2022 to $30.2B in 2025. Recent news highlights partnerships for sustainable packaging and upcoming Q2 2026 results. Despite negative net income margins and ROE, LYB maintains positive operating cash flow and a dividend payout.
LYB presents a cautious opportunity with analyst consensus leaning toward Buy (43.59%) and a $73.11 price target, suggesting 25% upside. Risks include persistent revenue declines, elevated debt, and industry headwinds, but cost-cutting and focus on high-margin polymers offer potential recovery. Investors should weigh the bullish technicals and analyst optimism against fundamental challenges in the chemical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
